Tasly gets Chinese rights to two cell therapies from Mesoblast

Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) received exclusive, Chinese rights to develop and commercialize

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE